Shaolin Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Shaolin Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-106,888	Closed	-$1.08M	–	839
2022 Q4	$1.08M	Hold	106,888	–	–	0.03%	349
2022 Q3	$1.06M	Hold	106,888	–	–	0.03%	410
2022 Q2	$1.06M	Hold	106,888	–	–	0.03%	457
2022 Q1	$1.05M	Hold	106,888	–	–	0.03%	452
2021 Q4	$1.05M	Buy	+106,888	New	+$1.05M	0.03%	440

Shaolin Capital Management's BIOT Position: Q1 2023 in Review

Shaolin Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 106,888 shares — an estimated $1.08M sold.

Shaolin Capital Management first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $1.08M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Shaolin Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Shaolin Capital Management sold 106,888 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.08M.
Shaolin Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Shaolin Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.08M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Shaolin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.